Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabor Liposits

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|January 31, 2025
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancerJulien Taieb, Marwan Fakih, Gabor Liposits, et al.
Future Oncology (London, England)|July 2, 2024
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
Therapeutic Advances in Medical Oncology|November 28, 2018
Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paperNicolò Matteo Luca Battisti, Nienke De Glas, Mina S Sedrak, et al.
The Lancet. Gastroenterology & Hepatology|March 11, 2019
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trialStine Braendegaard Winther, Gabor Liposits, Halla Skuladottir, et al.
Seminars in Radiation Oncology|March 21, 2022
The Evolution of Geriatric Oncology and Geriatric Assessment over the Past DecadeDarryl Outlaw, Maya Abdallah, Luiz A Gil-Jr, et al.
Journal of Geriatric Oncology|September 22, 2021
Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the Young International Society of Geriatric OncologyMark A Baxter, Joana Marinho, Enrique Soto-Perez-de-Celis, et al.
BMC Cancer|June 16, 2023
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)Louise Skau Rasmussen, Stine B Winther, Inna M Chen, et al.
Journal of Geriatric Oncology|September 20, 2023
The effect of BRAF<sup>V600E</sup> mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-studyGabor Liposits, Stine B Winther, Jesper Ryg, et al.
Journal of Geriatric Oncology|December 9, 2022
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-studyGabor Liposits, Jesper Ryg, Halla Skuladottir, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2022
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 studyThierry André, Alfredo Falcone, Yaroslav Shparyk, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|January 31, 2025
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancerJulien Taieb, Marwan Fakih, Gabor Liposits, et al.
Future Oncology (London, England)|July 2, 2024
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
Therapeutic Advances in Medical Oncology|November 28, 2018
Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paperNicolò Matteo Luca Battisti, Nienke De Glas, Mina S Sedrak, et al.
The Lancet. Gastroenterology & Hepatology|March 11, 2019
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trialStine Braendegaard Winther, Gabor Liposits, Halla Skuladottir, et al.
Seminars in Radiation Oncology|March 21, 2022
The Evolution of Geriatric Oncology and Geriatric Assessment over the Past DecadeDarryl Outlaw, Maya Abdallah, Luiz A Gil-Jr, et al.
Journal of Geriatric Oncology|September 22, 2021
Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the Young International Society of Geriatric OncologyMark A Baxter, Joana Marinho, Enrique Soto-Perez-de-Celis, et al.
BMC Cancer|June 16, 2023
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)Louise Skau Rasmussen, Stine B Winther, Inna M Chen, et al.
Journal of Geriatric Oncology|September 20, 2023
The effect of BRAF<sup>V600E</sup> mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-studyGabor Liposits, Stine B Winther, Jesper Ryg, et al.
Journal of Geriatric Oncology|December 9, 2022
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-studyGabor Liposits, Jesper Ryg, Halla Skuladottir, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2022
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 studyThierry André, Alfredo Falcone, Yaroslav Shparyk, et al.
Pageof 4